Company Overview - Harrow, Inc. is an eyecare pharmaceutical company focused on the discovery, development, and commercialization of ophthalmic pharmaceutical products, having transformed from a controversial compounder to a leading specialty pharma platform in U.S. eye care [2][4] - Founded in 2012 by Mark Baum, the company shifted from custom formulations to acquiring and scaling FDA-approved ophthalmic drugs through its own commercial infrastructure [2] Business Model - Harrow operates a three-segment model: Branded Pharmaceuticals, ImprimisRx, and Strategic Holdings, creating a self-reinforcing ecosystem that enhances physician relationships and drives growth through branded drugs [3] - The "Access for All" program serves as an in-house reimbursement engine, facilitating rapid adoption and high retention among doctors and patients [4] Financial Performance - Harrow has achieved compounding revenue growth exceeding 40% annually since 2014, supported by a disciplined acquisition strategy focused on late-stage or under-commercialized assets [4] - The company targets over $1 billion in annualized revenue and 30-40% EBIT margins by 2027, driven by expanding dry-eye penetration and entry into the $12 billion retina market [5] Market Position - With a market cap of under $1.4 billion, Harrow trades at approximately 5 times its estimated 2028 EBIT, indicating it operates as a scaled ophthalmic pharma platform rather than a niche compounder [6] - The investment case is strengthened by founder-led discipline, high insider ownership, and capital-light economics, despite recent stock depreciation of about 8.55% due to rising costs [7]